Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

Browse through some of the many highlights from TCT 2023 in San Francisco.

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

Research out of China found that the pairing proved to be more accurate in identifying cancer in nonmass-like lesions.

Researchers have shed light on the relationship between breast cancer screening and sociodemographic factors.

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer.